These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19037018)

  • 21. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual-source parallel radiofrequency excitation body MR imaging compared with standard MR imaging at 3.0 T: initial clinical experience.
    Willinek WA; Gieseke J; Kukuk GM; Nelles M; König R; Morakkabati-Spitz N; Träber F; Thomas D; Kuhl CK; Schild HH
    Radiology; 2010 Sep; 256(3):966-75. PubMed ID: 20720078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Focal liver lesions at 3.0 T: lesion detectability and image quality with T2-weighted imaging by using conventional and dual-source parallel radiofrequency transmission.
    Kukuk GM; Gieseke J; Weber S; Hadizadeh DR; Nelles M; Träber F; Schild HH; Willinek WA
    Radiology; 2011 May; 259(2):421-8. PubMed ID: 21330565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images.
    Gasperini C; Pozzilli C; Bastianello S; Giugni E; Horsfield MA; Koudriavtseva T; Galgani S; Paolillo A; Haggiag S; Millefiorini E; Fieschi C
    J Neurol Neurosurg Psychiatry; 1999 Nov; 67(5):579-84. PubMed ID: 10519861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis.
    Siddiqui MA; Wellington K
    CNS Drugs; 2005; 19(1):55-61; discussion 63-4. PubMed ID: 15651905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.
    Lacy M; Hauser M; Pliskin N; Assuras S; Valentine MO; Reder A
    Mult Scler; 2013 Nov; 19(13):1765-72. PubMed ID: 23652214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serial isotropic three-dimensional fast FLAIR imaging: using image registration and subtraction to reveal active multiple sclerosis lesions.
    Tan IL; van Schijndel RA; Pouwels PJ; Adèr HJ; Barkhof F
    AJR Am J Roentgenol; 2002 Sep; 179(3):777-82. PubMed ID: 12185063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI.
    Absinta M; Sati P; Fechner A; Schindler MK; Nair G; Reich DS
    AJNR Am J Neuroradiol; 2018 Jul; 39(7):1233-1238. PubMed ID: 29724768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic subtraction magnetic resonance imaging of cirrhotic liver: assessment of high signal intensity lesions on nonenhanced T1-weighted images.
    Yu JS; Kim YH; Rofsky NM
    J Comput Assist Tomogr; 2005; 29(1):51-8. PubMed ID: 15665683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibuprofen does not suppress active multiple sclerosis lesions on gadolinium-enhanced MR images.
    Barkhof F; van Waesberghe JH; Uitdehaag BM; Polman CH
    Ann Neurol; 1997 Dec; 42(6):982. PubMed ID: 9403493
    [No Abstract]   [Full Text] [Related]  

  • 32. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved Detection of Cortical Gray Matter Involvement in Multiple Sclerosis with Quantitative Susceptibility Mapping.
    Kakeda S; Futatsuya K; Ide S; Watanabe K; Miyata M; Moriya J; Ogasawara A; Sato T; Narimatsu H; Okada K; Uozumi T; Liu T; Wang Y; Korogi Y
    Acad Radiol; 2015 Nov; 22(11):1427-32. PubMed ID: 26342769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging.
    Hodel J; Outteryck O; Dubron C; Dutouquet B; Benadjaoud MA; Duhin E; Verclytte S; Zins M; Luciani A; Rahmouni A; Pruvo JP; Vermersch P; Leclerc X
    Radiology; 2016 Mar; 278(3):863-72. PubMed ID: 26436861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regional cervical cord atrophy and disability in multiple sclerosis: a voxel-based analysis.
    Valsasina P; Rocca MA; Horsfield MA; Absinta M; Messina R; Caputo D; Comi G; Filippi M
    Radiology; 2013 Mar; 266(3):853-61. PubMed ID: 23192778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
    Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F
    Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving Multiple Sclerosis Plaque Detection Using a Semiautomated Assistive Approach.
    van Heerden J; Rawlinson D; Zhang AM; Chakravorty R; Tacey MA; Desmond PM; Gaillard F
    AJNR Am J Neuroradiol; 2015 Aug; 36(8):1465-71. PubMed ID: 26089318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T1 hyperintense renal lesions: characterization with diffusion-weighted MR imaging versus contrast-enhanced MR imaging.
    Kim S; Jain M; Harris AB; Lee VS; Babb JS; Sigmund EE; Rueff LE; Taouli B
    Radiology; 2009 Jun; 251(3):796-807. PubMed ID: 19380690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acceleration of Double Inversion Recovery Sequences in Multiple Sclerosis With Compressed Sensing.
    Eichinger P; Hock A; Schön S; Preibisch C; Kirschke JS; Mühlau M; Zimmer C; Wiestler B
    Invest Radiol; 2019 Jun; 54(6):319-324. PubMed ID: 30720557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.
    Galassi S; Prosperini L; Logoteta A; Hirsch MN; Fanelli F; De Giglio L; Pozzilli C
    Mult Scler Relat Disord; 2016 Jul; 8():99-106. PubMed ID: 27456883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.